Nektar Therapeutics (NASDAQ:NKTR)

88.21
Delayed Data
As of 4:15pm ET
 +1.76 / +2.04%
Today’s Change
12.50
Today|||52-Week Range
99.02
+47.71%
Year-to-Date
3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb
Feb 16 / TheStreet.com - Paid Partner Content
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
Feb 15 / Zacks.com - Paid Partner Content
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
Feb 16 / Zacks.com - Paid Partner Content
Nektar (NKTR) Surges: Stock Moves 11% Higher
Feb 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close86.45
Today’s open86.59
Day’s range86.59 - 90.96
Volume2,382,698
Average volume (3 months)2,610,282
Market cap$13.6B
Data as of 4:15pm ET, 02/22/2018

Growth & Valuation

Earnings growth (last year)-80.33%
Earnings growth (this year)+31.82%
Earnings growth (next 5 years)-7.38%
Revenue growth (last year)-28.32%
P/E ratioNM
Price/Sales10.35
Price/Book150.30

Competitors

 Today’s
change
Today’s
% change
AVXSAveXis Inc+2.83+2.43%
ONCESpark Therapeutics I...+2.85+5.55%
XONIntrexon Corp-0.08-0.62%
JUNOJuno Therapeutics In...-0.08-0.09%
Data as of 4:02pm ET, 02/22/2018

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)-$0.34
Annual revenue (last year)$165.4M
Annual profit (last year)-$153.5M
Net profit margin-92.80%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Howard W. Robin
Chief Operating Officer &
Senior Vice President
John Nicholson
Corporate headquarters
San Francisco, California

Forecasts